CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

NitazoxanideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (11)

Name (Synonyms) Correlation
drug715 Ivermectin Wiki 0.53
drug308 Chloroquine Wiki 0.53
drug1611 non interventional Wiki 0.50
drug514 Fibrin generation markers assays Wiki 0.50
drug1478 Vitamin Super B-Complex Wiki 0.50
drug953 Other drugs Wiki 0.50
drug1394 Thrombin generation test assay Wiki 0.50
drug884 Niclosamide Wiki 0.35
drug505 Favipiravir Wiki 0.15
drug129 Azithromycin Wiki 0.09
drug1016 Placebo Wiki 0.04

Correlated MeSH Terms (8)

Name (Synonyms) Correlation
D001416 Back Pain NIH 0.50
D017116 Low Back Pain NIH 0.50
D010146 Pain NIH 0.50
D004211 Disseminated Intravascular Coagulation NIH 0.29
D020141 Hemostatic Disorders NIH 0.20
D001778 Blood Coagulation Disorders NIH 0.20
D018352 Coronavirus Infections NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.03

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0005521 Disseminated intravascular coagulation HPO 0.29
HP:0001928 Abnormality of coagulation HPO 0.25

There are 4 clinical trials

Clinical Trials

1 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19

COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.

NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs

Primary Outcomes

Description: the estimated number of patients with decreased viral load

Measure: Number of patients with decreased viral load

Time: 6 months

2 Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment

Efficacy of Ivermectin and Nitazoxanide in COVID-19 treatment

NCT04351347 COVID Drug: Chloroquine Drug: Nitazoxanide Drug: Ivermectin

Primary Outcomes

Description: Number of patients with virological cure

Measure: Number of patients with virological cure

Time: 6 months

3 A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers

NCT04359680 COVID-19 Viral Respiratory Illnesses Drug: Nitazoxanide Drug: Placebo Dietary Supplement: Vitamin Super B-Complex

Primary Outcomes

Measure: The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.

Time: Up to 6 weeks

Measure: The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.

Time: Up to 6 weeks

4 Novel Treatment Regimens in Treatment of COVID-19

Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

NCT04382846 COVID Corona Virus Infection Drug: Nitazoxanide Drug: Ivermectin Drug: Chloroquine Drug: Azithromycin
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: the number of patients with virological cure

Measure: Number of patients with virological cure

Time: 6 months

No related HPO nodes (Using clinical trials)